Skip to main content
NVDA-0.02%AAPL-0.17%GOOGL+0.59%MSFT-0.02%AMZN-0.02%TSM-1.68%SPCX+0.43%AVGO-0.97%META-0.04%TSLA+0.11%SKHY-5.20%MU+0.08%BRK-B+0.06%LLY-0.10%JPM-0.32%WMT-0.09%AMD-3.36%V-0.05%XOM+0.61%ASMLa-1.66%JNJ-0.27%INTC-5.57%MA-0.38%0700.HK-1.94%1398.HK+0.79%ORCL-5.23%ABBV+1.62%BAC-0.18%CSCO-1.82%CVX-0.50%COST-0.02%KO+0.32%LRCX-5.65%CAT-1.29%AP2d-1.55%0005.HK-0.78%AMAT-3.17%UNH-1.22%HSBA.L-1.30%DELL-5.35%PG+0.25%MS-1.22%GE-0.39%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.03%HD-1.53%0939.HK+1.66%GS-0.88%NZDJPY-2.59%AUDJPY-1.80%CHFJPY-1.61%NZDCAD-1.46%NZDUSD-1.44%EURNZD+1.43%GBPNZD+1.39%GBPJPY-1.21%EURJPY-1.21%USDJPY-1.18%CADJPY-1.15%NZDCHF-1.02%USDSEK+0.99%USDZAR+0.97%USDNOK+0.88%AUDNZD+0.81%EURSEK+0.79%EURZAR+0.77%USDTHB+0.72%GBPZAR+0.70%AUDCAD-0.68%EURNOK+0.67%AUDUSD-0.64%AUDDKK-0.62%EURAUD+0.60%CHFSEK+0.60%USDMXN+0.58%GBPAUD+0.58%AUDSGD-0.55%USDPLN+0.49%CHFNOK+0.48%USDCHF+0.45%CADCHF+0.44%NZDSGD-0.43%GBPTRY+0.41%EURCHF+0.40%GBPCHF+0.38%GBPHKD+0.32%NOKJPY-0.31%USDSGD+0.30%GBPMXN-0.28%EURPLN+0.28%SGDJPY+0.27%USDDKK+0.21%EURHKD-0.21%AUDCHF-0.20%USDILS+0.16%NZDMXN-0.16%USDTRY+0.11%USDCNH+0.11%CHFSGD-0.10%EURSGD+0.09%EURCNH-0.08%GBPCAD-0.08%PLNJPY+0.07%EURCAD-0.06%GBPUSD-0.04%EURUSD-0.04%USDCOP-0.04%AUDNOK+0.03%EURCZK-0.03%EURGBP+0.02%USDHKD+0.02%GBPSGD+0.02%USDCAD-0.01%EURDKK+0.01%UKOIL+6.49%USOIL+6.40%XPTUSD-6.24%GAGUSD-5.47%XAGUSD-5.47%HG1-4.78%GAUUSD-1.92%XAUUSD-1.92%XNGUSD+1.68%SUGAR0.00%S10.00%COFFEE0.00%BTCUSD-1.32%ETHUSD-0.21%USDTUSD-0.02%XRPUSD-2.96%SOLUSD-1.53%TRXUSDT+0.12%ZECUSDT-9.33%DOGEUSD-2.24%XMRUSDT+0.03%LINKUSD-1.68%XLMUSD-1.77%BCHUSDT-9.71%LTCUSD-1.57%UNIUSD-1.34%TONUSD+24.88%HBARUSDT-1.85%SUIUSD-3.99%TAOUSDT-5.72%AAVEUSD-2.22%DOTUSDT-1.47%ICPUSDT+1.08%ONDOUSDT-3.31%WLDUSDT-3.15%ATOMUSDT-2.16%ARBUSDT-1.88%JUPUSDT-2.53%INJUSDT-2.62%STXUSDT-4.53%FETUSDT-2.47%TIAUSDT-1.39%PYTHUSDT-1.26%SEIUSDT-6.02%IMXUSDT-3.85%WIFUSDT-4.89%GRTUSDT-3.53%OPUSDT-3.00%POLUSDT-4.85%IOTAUSDT-4.24%AXSUSDT-2.36%FARTCOINUSDT-3.35%EOSUSDT-2.29%DYDXUSDT-1.75%ORDIUSDT-1.01%GALAUSDT-3.65%NOTUSDT-2.97%RONINUSDT-2.64%NVDA-0.02%AAPL-0.17%GOOGL+0.59%MSFT-0.02%AMZN-0.02%TSM-1.68%SPCX+0.43%AVGO-0.97%META-0.04%TSLA+0.11%SKHY-5.20%MU+0.08%BRK-B+0.06%LLY-0.10%JPM-0.32%WMT-0.09%AMD-3.36%V-0.05%XOM+0.61%ASMLa-1.66%JNJ-0.27%INTC-5.57%MA-0.38%0700.HK-1.94%1398.HK+0.79%ORCL-5.23%ABBV+1.62%BAC-0.18%CSCO-1.82%CVX-0.50%COST-0.02%KO+0.32%LRCX-5.65%CAT-1.29%AP2d-1.55%0005.HK-0.78%AMAT-3.17%UNH-1.22%HSBA.L-1.30%DELL-5.35%PG+0.25%MS-1.22%GE-0.39%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.03%HD-1.53%0939.HK+1.66%GS-0.88%NZDJPY-2.59%AUDJPY-1.80%CHFJPY-1.61%NZDCAD-1.46%NZDUSD-1.44%EURNZD+1.43%GBPNZD+1.39%GBPJPY-1.21%EURJPY-1.21%USDJPY-1.18%CADJPY-1.15%NZDCHF-1.02%USDSEK+0.99%USDZAR+0.97%USDNOK+0.88%AUDNZD+0.81%EURSEK+0.79%EURZAR+0.77%USDTHB+0.72%GBPZAR+0.70%AUDCAD-0.68%EURNOK+0.67%AUDUSD-0.64%AUDDKK-0.62%EURAUD+0.60%CHFSEK+0.60%USDMXN+0.58%GBPAUD+0.58%AUDSGD-0.55%USDPLN+0.49%CHFNOK+0.48%USDCHF+0.45%CADCHF+0.44%NZDSGD-0.43%GBPTRY+0.41%EURCHF+0.40%GBPCHF+0.38%GBPHKD+0.32%NOKJPY-0.31%USDSGD+0.30%GBPMXN-0.28%EURPLN+0.28%SGDJPY+0.27%USDDKK+0.21%EURHKD-0.21%AUDCHF-0.20%USDILS+0.16%NZDMXN-0.16%USDTRY+0.11%USDCNH+0.11%CHFSGD-0.10%EURSGD+0.09%EURCNH-0.08%GBPCAD-0.08%PLNJPY+0.07%EURCAD-0.06%GBPUSD-0.04%EURUSD-0.04%USDCOP-0.04%AUDNOK+0.03%EURCZK-0.03%EURGBP+0.02%USDHKD+0.02%GBPSGD+0.02%USDCAD-0.01%EURDKK+0.01%UKOIL+6.49%USOIL+6.40%XPTUSD-6.24%GAGUSD-5.47%XAGUSD-5.47%HG1-4.78%GAUUSD-1.92%XAUUSD-1.92%XNGUSD+1.68%SUGAR0.00%S10.00%COFFEE0.00%BTCUSD-1.32%ETHUSD-0.21%USDTUSD-0.02%XRPUSD-2.96%SOLUSD-1.53%TRXUSDT+0.12%ZECUSDT-9.33%DOGEUSD-2.24%XMRUSDT+0.03%LINKUSD-1.68%XLMUSD-1.77%BCHUSDT-9.71%LTCUSD-1.57%UNIUSD-1.34%TONUSD+24.88%HBARUSDT-1.85%SUIUSD-3.99%TAOUSDT-5.72%AAVEUSD-2.22%DOTUSDT-1.47%ICPUSDT+1.08%ONDOUSDT-3.31%WLDUSDT-3.15%ATOMUSDT-2.16%ARBUSDT-1.88%JUPUSDT-2.53%INJUSDT-2.62%STXUSDT-4.53%FETUSDT-2.47%TIAUSDT-1.39%PYTHUSDT-1.26%SEIUSDT-6.02%IMXUSDT-3.85%WIFUSDT-4.89%GRTUSDT-3.53%OPUSDT-3.00%POLUSDT-4.85%IOTAUSDT-4.24%AXSUSDT-2.36%FARTCOINUSDT-3.35%EOSUSDT-2.29%DYDXUSDT-1.75%ORDIUSDT-1.01%GALAUSDT-3.65%NOTUSDT-2.97%RONINUSDT-2.64%
EM

Editas Medicine, Inc. (EDIT)

NASDAQ • Healthcare

$2.65
-$0.12 (-4.3%)
Market closed

Last close at September 10, 2026 at 20:00 UTC

Open$2.74
Day Range$2.62 - $2.77
Avg. Volume (3M)2.6M
Market Cap$404.3M
52 Week Range
$1.66$4.54
Next EarningsIn 60 daysNov 9, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$11.8M100%
Gross Profitminus cost of goods$11.8M100%

Fundamentals & Financials

Revenue (TTM)
$47M
Net Income (TTM)
-$73.9M
EPS (TTM)
-$0.75
ROA (TTM)
-31.15%
Current Ratio
3.19
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+77.8%Q1 2026-$0.06
+13.3%Q2 2026-$0.26
+44.5%Q3 2026-$0.15
Next

Nov 9

in 60 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

View full earnings history

About Editas Medicine, Inc.

Editas Medicine, Inc. develops gene-editing medicines and trades on NASDAQ as EDIT in the healthcare sector's biotechnology field. The company builds its programs on a proprietary CRISPR-based platform and recorded $40.5 million of revenue in FY2025. It was founded in 2013, went public in 2016, and is based in Cambridge, Massachusetts.

Name
Editas Medicine, Inc.
CEO
Gilmore O'Neill
Website
www.editasmedicine.com
Industry
Healthcare
Year Founded
2013
Employees
87

Today's Snapshot

AI-generated

The day ended with EDIT 4.3% lower at 2.65, in line with a weaker sector.

Trading Volume

Below 10d avg (2.1M)

1.9M

vs S&P 500 Today

Strong Underperformance

-3.76%

Updated: September 10, 2026 at 20:15 UTC

Technical Indicators

1 Buy1 Neutral6 Sell
EDIT presents a clear negative profile with most short- and medium-term averages above the current price and VWAP also acting as resistance, while the trend-strength and momentum indicators are tilted to the downside. Volatility is relatively high and on-balance volume is subdued, reinforcing a sell-oriented market structure despite a couple of very short-term oscillators flashing oversold. The 200-day average is nearby but does not offset the broad weakness across shorter horizons. Technical takeaway: Strong Sell.
All signals
  • EMA (5 indicators)$2.80 - $2.99
    Sell
  • RSI (14)39.63
    Neutral
  • Stochastic %K (14, 3, 3)7.41
    Buy
  • MACD Level (12, 26)-0.00
    Sell

Peers & Related Assets

ALLOAllogene Therapeutics, Inc.
$1.76+1.7%
CAPRCapricor Therapeutics, Inc.
$8.3-3.9%
AVIRAtea Pharmaceuticals, Inc.
$5.18-1.7%
VNDAVanda Pharmaceuticals Inc.
$5.04-4.0%
VYGRVoyager Therapeutics, Inc.
$3.19-1.9%
CABACabaletta Bio, Inc.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.